FILIPPE BARCELLOS FILIPPINI
Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Combined transcatheter aortic valve replacement and left atrial appendage occlusion in patients ineligible for oral anticoagulation: A case series(2022) FREIRE, A. F. D.; FILIPPINI, F. B.; BIGNOTO, T. C.; BRITO, P. H. F. de; NICZ, P. F. G.; MELO, P. H. M. C. D.; SILVA, R. C. e; QUEIROGA, M.; RIBEIRO, H. B.; PROCóPIO, A. G. M.; BEZERRA, C. G.; GRUBE, E.; ABIZAID, A.; FILHO, R. K.; BRITO JR., F. S. dePatients presenting with aortic stenosis and atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR) are commonly at increased risk for stroke and bleeding complications. Concomitant left atrial appendage occlusion (LAAO) after TAVR may be an alternative to oral anticoagulation (OAC). Between 2018 and 2022, 7 consecutive patients who were ineligible for OAC underwent simultaneous TAVR and LAAO. The mean age was 84.9 ± 4.9 years. The mean CHA2DS2-VASc, HAS-BLED, and STS predicted risk of mortality scores were 5.9 ± 0.7, 3.9 ± 1.1, and 8.8 ± 3.4%, respectively. The median follow-up time was 23 (1 to 27) months. All procedures achieved technical success and no adverse events were observed during follow-up. This case series shows that concomitant TAVR and LAAO is feasible and safe among patients with severe aortic stenosis and AF who are deemed ineligible for OAC. Learning objectives: Atrial fibrillation is the most common arrhythmia in the transcatheter aortic valve replacement (TAVR) population. In those who experience major or life-threatening bleeding, mortality is doubled. We report a case series of 7 concomitant left atrial appendage occlusions (LAAO) after TAVR in patients ineligible for oral anticoagulation. All procedures achieved technical success and no adverse events were observed. The simultaneous approach with TAVR and LAAO was feasible and safe in this case series.
conferenceObject Percutaneous Tricuspid Valve-in- Valve Implantation in Failed Surgical Bioprosthetic Valves: Brazilian Single Center Registry(2023) FILIPPINI, Filippe; BRATZ, Guilherme; SESSA, Bruno; MOREIRA, Cauyna Gurgel; HATTORI, Mario; COIMBRA, Germana; CASSAR, Renata; FREIRE, Antonio Fernando; RIBEIRO, Henrique; ABIZAID, Alexandre; BRITO JR., Fabio; ARRIETA, RaulconferenceObject Noncontrast Transcatheter Aortic Valve Implantation for Patients With Aortic Stenosis and Chronic Kidney Disease: Long-Term Follow-Up of The Pilot Study(2023) FILIPPINI, Filippe; FREIRE, Antonio Fernando; NICZ, Pedro; BRATZ, Guilherme; SESSA, Bruno; RIBEIRO, Henrique; ACCORSI, Tarso; LIBERATO, Gabriela; NOMURA, Cesar Higa; CASSAR, Renata; VIEIRA, Marcelo; BIHAN, David Le; BARRETTO, Rodrigo; MATHIAS, Wilson; POMERANTZEFF, Pablo; TARASOUTCHI, Flavio; ABIZAID, Alexandre; BRITO JR., Fabio- Percutaneous Strategies in Structural Heart Diseases: Focus on Chronic Heart Failure(2023) FILIPPINI, Filippe Barcellos; RIBEIRO, Henrique Barbosa; BOCCHI, Edimar; BACAL, Fernando; MARCONDES-BRAGA, Fabiana G.; AVILA, Monica S.; STURMER, Janine Daiana; MARCHI, Mauricio Felippi de Sa; KANHOUCHE, Gabriel; FERNANDO, Antonio; CASSAR, Renata; JR, Fabio Sandoli de Brito; ABIZAID, Alexandre A.Innovations in devices during the last decade contributed to enhanced diagnosis and treatment of patients with cardiac insufficiency. These tools progressively adapted to minimally invasive strategies with rapid, widespread use. The present article focuses on actual and future directions of device-related diagnosis and treatment of chronic heart failure.
conferenceObject Transcatheter aortic valve implantation without contrast media technique in chronic kidney disease population - pilot study(2022) NICZ, P.; FREIRE, A. F. D.; FILIPPINI, F. B.; KANHOUCHE, G.; ACCORSI, T. A. D.; RIBEIRO, H. B.; LIBERATO, G.; NOMURA, C. H.; CASSAR, R. S.; VIEIRA, M. L.; MATHIAS, W.; POMERANTZEFF, P. M. A.; TARASOUTCHI, F.; ABIZAID, A.; BRITO JR., F. S. De- Non-contrast transcatheter aortic valve implantation for patients with aortic stenosis and chronic kidney disease: a pilot study(2023) FREIRE, Antonio Fernando Diniz; NICZ, Pedro Felipe Gomes; RIBEIRO, Henrique Barbosa; FILIPPINI, Filippe Barcellos; ACCORSI, Tarso Duenas; LIBERATO, Gabriela; NOMURA, Cesar Higa; CASSAR, Renata de Sa; VIEIRA, Marcelo Luiz Campos; JR, Wilson Mathias; POMERANTZEFF, Pablo Maria Alberto; TARASOUTCHI, Flavio; ABIZAID, Alexandre; FILHO, Roberto Kalil; JR, Fabio Sandoli de BritoBackgroundAcute kidney injury (AKI) is frequently observed after transcatheter aortic valve implantation (TAVI). Of note, it is associated with a threefold increase in all-cause and cardiac death. We propose a new non-contrast strategy for evaluating and performing the TAVI procedure that can be especially valuable for patients with aortic stenosis (AS) and chronic kidney disease (CKD) to prevent AKI. MethodsPatients with severe symptomatic AS and CKD stage & GE;3a were evaluated for TAVI using four non-contrast imaging modalities for procedural planning: transesophageal echocardiogram (TEE), cardiac magnetic resonance, multidetector computed tomography (MDCT), and aortoiliac CO2 angiography. Patients underwent transfemoral (TF) TAVI using the self-expandable Evolut R/Pro, and the procedures were guided by fluoroscopy and TEE. Contrast MDCT and contrast injection at certain checkpoints during the procedure were used in a blinded fashion to guarantee patient safety. ResultsA total of 25 patients underwent TF-TAVI with the zero-contrast technique. The mean age was 79.9 & PLUSMN; 6.1 years, 72% in NYHA class III/IV, with a mean STS-PROM of 3.0% & PLUSMN; 1.5%, and creatinine clearance of 49 & PLUSMN; 7 ml/min. The self-expandable Evolut R and Pro were implanted in 80% and 20% of patients, respectively. In 36% of the cases, the transcatheter heart valve (THV) chosen was one size larger than the one by contrast MDCT, but none of these cases presented adverse events. Device success and the combined safety endpoint (at 30 days) both achieved 92%. Pacemaker implantation was needed in 17%. ConclusionThis pilot study demonstrated that the zero-contrast technique for procedural planning and THV implantation was feasible and safe and might become the preferable strategy for a significant population of CKD patients undergoing TAVR. Future studies with a larger number of patients are still needed to confirm such interesting findings.